Literature DB >> 34536158

Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells.

Rui Wang1,2, Hui Guo1,2, Xiaotong Tang1, Tiantian Zhang1, Yang Liu1, Cheng Zhang1,2, Hanbing Yu1, Yumei Li3.   

Abstract

Immunosuppression developed by cancer cells remains a leading cause of treating failure of immunotherapies. This study aimed to explore the function of human endogenous retrovirus-H long terminal repeat-associating 2 (HHLA2), an immune checkpoint molecule from the B7 family, in the immune escape in hepatocellular carcinoma (HCC). Mouse models with primary HCC or with xenograft tumors were established. The portion of tumor-associated macrophages (TAMs) and the level of PD-L1 in the tumor tissues were examined. THP-1 cells were treated with PMA to obtain a macrophage-like phenotype. The PMA-treated THP-1 cells were co-cultured with the HCC cells in Transwell chambers to examine the function of HHLA2 in chemotactic migration and polarization of macrophages. HHLA2 expression was correlated with infiltration of immune cells, especially macrophages, and was linked to poor prognosis of patients with HCC. HHLA2 knockdown reduced incidence rate of primary HCC in mice. It also reduced tumor metastasis, the portion of M2 macrophages, and the expression of PD-L1 in primary and xenograft tumors. In vitro, HHLA2 upregulation increased expression of PD-L1 in HCC cells indirectly by inducing M2 polarization and chemotactic migration of macrophages. Interferon gamma (IFNG) enhanced expression of interferon regulatory factor 1 (IFR1) in HCC cells, and IFR1 bound to the promoter region of HHLA2 to activate HHLA2 expression. This study suggested that the IFNG/IFR1/HHLA2 axis in HCC induces M2 polarization and chemotactic migration of macrophages, which leads to immune escape and development of HCC.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  HHLA2; IFNG; IFR1.; PD-L1; hepatocellular carcinoma; immune escape; tumor-associated macrophages

Mesh:

Substances:

Year:  2021        PMID: 34536158     DOI: 10.1007/s10753-021-01547-3

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  26 in total

Review 1.  Delivery technologies for cancer immunotherapy.

Authors:  Rachel S Riley; Carl H June; Robert Langer; Michael J Mitchell
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

Review 2.  Immunotherapy for lung cancer.

Authors:  Antonius Steven; Scott A Fisher; Bruce W Robinson
Journal:  Respirology       Date:  2016-04-21       Impact factor: 6.424

Review 3.  Mechanisms of immune evasion by tumors.

Authors:  Charles G Drake; Elizabeth Jaffee; Drew M Pardoll
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

4.  New Clinical Approaches and Emerging Evidence on Immune-Checkpoint Inhibitors as Anti-Cancer Therapeutics: CTLA-4 and PD-1 Pathways and Beyond.

Authors:  Maria-Ioanna Christodoulou; Apostolos Zaravinos
Journal:  Crit Rev Immunol       Date:  2019       Impact factor: 2.214

5.  Immunotherapy for hepatocellular carcinoma.

Authors:  Yin Zongyi; Li Xiaowu
Journal:  Cancer Lett       Date:  2019-12-04       Impact factor: 8.679

6.  Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.

Authors:  Rafael Winograd; Katelyn T Byrne; Rebecca A Evans; Pamela M Odorizzi; Anders R L Meyer; David L Bajor; Cynthia Clendenin; Ben Z Stanger; Emma E Furth; E John Wherry; Robert H Vonderheide
Journal:  Cancer Immunol Res       Date:  2015-02-12       Impact factor: 11.151

Review 7.  Cancer immunotherapy: harnessing the immune system to battle cancer.

Authors:  Yiping Yang
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

Review 8.  Hepatocellular carcinoma in the era of immunotherapy.

Authors:  Hao-Wen Sim; Jennifer Knox
Journal:  Curr Probl Cancer       Date:  2017-11-15       Impact factor: 3.187

Review 9.  Immunotherapy and Prevention of Pancreatic Cancer.

Authors:  Alexander H Morrison; Katelyn T Byrne; Robert H Vonderheide
Journal:  Trends Cancer       Date:  2018-04-30

10.  Prognostic Significance of Potential Immune Checkpoint Member HHLA2 in Human Tumors: A Comprehensive Analysis.

Authors:  Ben Wang; Zhujie Ran; Mengmeng Liu; Yunsheng Ou
Journal:  Front Immunol       Date:  2019-07-15       Impact factor: 7.561

View more
  2 in total

1.  Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma.

Authors:  Lin Ding; Qian Yu; Shuo Yang; Wen-Jing Yang; Te Liu; Jing-Rong Xian; Tong-Tong Tian; Tong Li; Wei Chen; Bei-Li Wang; Bai-Shen Pan; Jian Zhou; Jia Fan; Xin-Rong Yang; Wei Guo
Journal:  Front Immunol       Date:  2022-03-17       Impact factor: 7.561

Review 2.  Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy.

Authors:  Honggang Ying; Jian Xu; Xiaozhen Zhang; Tingbo Liang; Xueli Bai
Journal:  EBioMedicine       Date:  2022-04-16       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.